Đang chuẩn bị liên kết để tải về tài liệu:
Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, doubleblind, placebo-controlled, parallel group, multi-center, phase II trial
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Pirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive fibrotic lung diseases, in which conventional anti-inflammatory therapy is not sufficiently effective and antifibrotic therapies may offer a novel treatment option. |